Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMB 101 - IMBiologics

Next Previous
Drug Profile

IMB 101 - IMBiologics

Alternative Names: IMB-101 - IMBiologics; NAV-240; OX40LxTNFα bispecific antibody - IMBiologics; OXTIMA

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HK inno.N
  • Developer HK inno.N; Navigator Medicines
  • Class Anti-inflammatories; Bispecific antibodies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa
  • Phase I Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 27 Mar 2026 Pharmacokinetics and adverse event data from a phase Ia/Ib trial in Rheumatoid arthritis presented at the Annual Meeting of American Academy of Dermatology (AAD-2026)
  • 27 Mar 2026 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Healthy volunteers released by Navigator Medicines
  • 08 Jan 2026 IMB 101 licensed to Navigator Medicines worldwide

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top